Skip to content

SI-BONE, Inc. SIBN Return on equity

Return on equity at other companies

Zimmer Biomet Holdings logo
Zimmer Biomet HoldingsZBH
6.1%-1.2pp
Globus Medical logo
Globus MedicalGMED
13.3%+8.7pp
Alphatec Holdings logo
Alphatec HoldingsATEC
-812.1%
Medtronic logo
MedtronicMDT
9.8%+0.4pp
IAR
Integra LifeSciencesIART
-38.6%
Bioventus logo
BioventusBVS
16.9%+10.9pp

Other financials

Income statement

See full
Revenue$52.6M+11.2%
Gross profit$41.9M+11.3%
Operating income-$5.1M+31.9%
Net income-$4.3M+33.8%
EPS (diluted)-$0.10+33.3%

Balance sheet

See full
Cash & equivalents$33.5M-18.6%
Total debt$42.9M+15.6%
Total equity$178.9M+7.0%
Total assets$242.7M+6.8%

Cash flow

See full
Operating cash flow-$2.4M+51.9%
CapEx$1.1M-48.0%
Free cash flow-$3.4M+50.8%

Valuation

See full
Market cap$743.29M+6.4%
Enterprise value$752.71M+8.4%
P/S3.6×-0.4×

Profitability

See full
Gross margin79.6%+0.3pp
Operating margin-9.7%-3.0pp
Net margin-8.1%-2.6pp
FCF margin-2.9%-1.2pp

Returns & leverage

See full
Debt / equity0.2×0.0×
Current ratio10×+1.5×

Where this comes from

Calculated from SI-BONE, Inc.’s reported figures.

Based on trailing twelve months.

The official record: SI-BONE, Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about SI-BONE, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is SI-BONE, Inc.'s return on equity?
SI-BONE, Inc. (SIBN) reported return on equity of -9.6% in Q1 2026.
How has SI-BONE, Inc.'s return on equity changed year-over-year?
SI-BONE, Inc.'s return on equity increased by 39.6% year-over-year, from -16% to -9.6%.
What is the long-term trend for SI-BONE, Inc.'s return on equity?
Over 5 years (2020 to 2025), SI-BONE, Inc.'s return on equity has grown at a -21.8% compound annual growth rate (CAGR), from -37.6% to -11%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.